Quarterly Return of HIV clinic/ART center Name of the HIV Clinic/ ART Center Period of the return (Quarter of 20____) (Revision-01.01. 2018)

Completed returns should be sent to Director/NSACP, C/O SIM unit, 29, De Saram Place, Colombo 10 by post or by fax to 011 2665277 on or before 20th of the month following each quarter

Indicator		Stage	No. Patients	Clinic File Numbers
1.1	Number of patients newly enrolled in HIV care during this quarter (Include all new patients. Exclude transfer-in patients. Transfer-in patients should be included in row 1.4)	(Both Pre ART and ART)		
1.2	Newly started on ART during this Quarter (Include both new and old patients newly started on ART)	1.2 ART		
1.3	Restarted ART after stopping or loss to follow up	1.3 ART		
.4	Number of patients Transferred-in during this quarter	1.4.1 Pre ART		
		1.4.2 ART		
1.5	Number of patients Transferred-out during this quarter	1.5.1 Pre ART		
		1.5.2 ART		
1.6	Number of patients Stopping ART during this quarter (Include if ART stopped due to medical reasons)	1.6.1 ART		
	Number of patients who Lost to Follow Up during this quarter (Include patients who have defaulted for more than 3 months from the	1.7.1 Pre ART		
1.7	last previous Quarter)	1.7.2 ART		
1.8	Number of patients Re-entered the clinic after loss to follow up during this quarter (Include patients who have defaulted for more	1.8.1 Pre ART		
	than 3 months and came back for clinic follow up)	1.8.2 ART		
1.9	Number of Deaths during this quarter	1.9.1 Pre ART		
		1.9.2 ART		

2. Details of opportunistic infections during this quarter (Include both Pre-ART and ART patients, source: patient record section 11, 7th column on OI, include both presumptive and confirmed cases)						
Opportunistic infection	Number of patients	Opportunistic infection	Number of patients			
2. 1. Newly diagnosed active TB (Both PTB and EPTB)		2. 7. Cryptococcal Meningitis				
2. 2. Candidiasis (include only oral or oesophageal)		2. 8. Toxoplasmosis				
2. 3. Chronic Diarrhoea		2. 9. CMV (any of the end organ diseases)				
2. 4. Pneumocystis jiroveci pneumonia (PJP)		2.10. Mycobacterium avium complex (MAC)				
2. 5. Herpes Zoster		2. 11 Other				
2. 6. Pneumonia		2. 12 Other				

3. PMTCT (source: From a separate register for PMTCT)		Age in years	
		25+	Total
3.1 Number of HIV-positive pregnant women under care at the beginning of this quarter (3.6 of previous quarter)			
3.2 Number of new HIV-positive pregnant women enrolled during this quarter			
 3.2.1 Number of HIV-positive women who are already in HIV care who got pregnant during this quarter 			
3.2.2 Number of pregnant women newly identified with HIV during this quarter			
3.3 Pregnancy outcome by the end of this quarter			•
3.3.1 Number of normal vaginal deliveries			
3.3.2 Number of cesarean sections			
3.3.3 Number of other modes of deliveries			
3.3.4 Total number of deliveries (3.3.1+3.3.2+3.3.3)			
3.3.5 Number of live births during this quarter			
3.3.6 Number of fetal wastage during this quarter			
3.4 Number of infants who received an HIV Virological Test* within two months of birth during this quarter			
3.5 Number of infants who had positive HIV Virological Tests* during this quarter			
3.6 Total number of pregnant women on ARV at the end of this quarter			

^{(*} DNA or RNA PCR testing)

4. TB/ HIV Co-infection during this quarter (Sources: TB screening register, Patient record, Pre-ART and ART		Newly enrolled PLHIV during the quarter			Previously enrolled PLHIV attended during this quarter				
registers)		Adults (15+)		Children (<15)		Adults (15+)		Children (<15)	
Note: 1. Transfer in patients to be considered as newly enrolled 2. If a PLHIV has both PTB and EPTB include only as Pulmonary TB		Male	Female	Male	Female	Male	Female	Male	Female
4.1 Number of patients on anti-TE	3 treatment at the time of diagnosis of HIV								
4.2 Number of HIV positive patier	nts having past history of TB								
4.3 Number of HIV positive patients symptomatically screened for TB during last visit									
4.4 Number of HIV positive patier	nts referred for TB screening								
	4.4.1 Latent TB infection								
	4.4.2 Pulmonary TB (Sputum Smear +ve)								
	4.4.3 Pulmonary TB (Sputum Smear -ve)								
4.4 Of them, (4.4) number of;	4.4.4 Extra Pulmonary TB								
	4.4.5 MDR/XDR or TDR TB								
	4.4.6 Other								
	4.4.7 No feedback								
4.5 Number of patients on INAH	prophylaxis therapy (IPT)								
4.6 Number of patients on co-trim	noxazole preventive therapy (CPT)								

5. HIV/ HBV and/or HCV co-infections during this quarter		Newly enrolled PLHIV during the quarter				Previously enrolled PLHIV attended during this quarter			
	Adults	Adults (15+)		Children (<15)		Adults (15+)		en (<15)	
	Male	Female	Male	Female	Male	Female	Male	Female	
5.1 Number tested for Hepatitis B by using HBsAg									
5.2 Number diagnosed with Hepatitis B acute or chronic infection									
5.3 Number tested for Hepatitis C using anti HCV antibody testing									
5.4 Number of diagnosed with acute or chronic Hepatitis C infection									

6. Details of Non communicable diseases and other sexually transmitted infections among PLHIV during this quarter							
Non Communicable Disease	Number of patients	Other Sexually transmitted infections	Number of patients				
6.1 Diabetes Mellitus		6.10 Early syphilis					
6.2 Dyslipidaemia which need medication		6.11Gonorrhoea					
6.3 Ischaemic heart disease		6.12 Non-gonococcal infections					
6.4 Renal disease (eGFR <60 ml/min/m ²		6.13 Newly diagnosed HSV					
6.5 Bone changes (Dexa scan moderate to severe)		6.14 Newly diagnosed HPV					
6.6 Malignancies		3.15 Pap changes					
6.7 Hypertension which need medication		6.16 Other STIs					
6.8 Blood dyscrasis (anemia, thrombocytopenia etc,)							
6.9 Other							

7. HIV-1 Drug Resistance Testing among ART experie	nced patients	Number of patients
7.1 Number of samples sent for ARV resistance testing d	uring this quarter	
7.2 Number of reports received for resistance testing duri	ng this quarter	
7.2.1 Resistance to at least one NRTI		
7.2.2 Resistance to at least one NNRTI		
7.2.3 Resistance to at least one PI		
7.2.4 Resistance to at least any other drug cate	gory	
7.2.5 Resistance to more than one ARV		
7.2.6 No resistance to ARV		
7.2.7 Total no of reports (= 7.2)		
Return completed by (Name and designation) Checked by (Name and designation) Date of completion Comments:	:	